TREE NEWS update: Chongqing Chen’an Biopharmaceutical, a controlling subsidiary of Zhifei Biological, has received acceptance notices (CXSS2600146, CXSS2600147) from China’s National Medical Products Administration for its self-developed biosimilar semaglutide injection. The product is intended for glycemic control in adults with type 2 diabetes.
Zhifei’s Semaglutide Injection Gets NMPA Filing Acceptance for Type 2 Diabetes
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
33m ago
Meili Tech denies Tesla suspension spring supply
57m ago
Saxo warns yen strength may trigger crowded trade unwind
1h ago
Apple’s foldable iPhone initial output reportedly just hundreds a day
1h ago
Amazon Mandates Banks for First Sterling Bond Sale
1h ago
Yen traders eye 100 per dollar as extreme but possible
1h ago
Hang Seng Index closes down 0.38%; TECH Index falls 1.28%